Target type: molecularfunction
Binding to the cytokine, macrophage migration inhibitory factor. [GOC:BHF, PMID:19601712]
Macrophage migration inhibitory factor (MIF) binding is a complex process that involves the interaction of MIF with its cognate receptor, CD74, and the subsequent activation of downstream signaling pathways. This interaction plays a crucial role in a wide range of biological processes, including inflammation, immunity, and cancer.
MIF is a pro-inflammatory cytokine that is produced by various cells, including macrophages, lymphocytes, and epithelial cells. It is involved in the regulation of immune responses, particularly in the activation of macrophages and T cells. MIF binds to CD74, which is a type I transmembrane protein that is widely expressed on various cell types. Upon binding to CD74, MIF triggers a cascade of intracellular signaling events.
The molecular mechanisms underlying MIF-mediated signaling are not fully understood, but several pathways have been implicated. One pathway involves the activation of the MAPK signaling cascade, leading to the phosphorylation of ERK, JNK, and p38 MAP kinases. These kinases play important roles in regulating cell proliferation, differentiation, and survival.
Another pathway involves the activation of the PI3K/Akt signaling pathway, which promotes cell survival and inhibits apoptosis. MIF binding to CD74 can also activate the NF-κB signaling pathway, which is a key regulator of inflammation and immune responses.
The activation of these signaling pathways by MIF has been shown to have diverse effects on cells. MIF promotes the recruitment and activation of macrophages, the production of inflammatory cytokines, and the proliferation and survival of cancer cells.
Overall, MIF binding to CD74 is a critical event that initiates a series of intracellular signaling pathways that regulate a variety of biological processes. This interaction plays a significant role in inflammation, immunity, and cancer development. The precise molecular mechanisms underlying these effects are still under investigation, but further research is expected to provide a better understanding of the role of MIF in health and disease.'
"
Protein | Definition | Taxonomy |
---|---|---|
COP9 signalosome complex subunit 5 | A COP9 signalosome complex subunit 5 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q92905] | Homo sapiens (human) |
HLA class II histocompatibility antigen gamma chain | An MHC class II histocompatibility antigen gamma chain that is encoded in the genome of human. [PRO:WCB, UniProtKB:P04233] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
8-mercaptoquinoline | 8-mercaptoquinoline: structure given in first source | ||
crizotinib | crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER. | 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine | antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |
pf-06463922 | lorlatinib : A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer. lorlatinib: inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein | aminopyridine; aromatic ether; azamacrocycle; benzamides; cyclic ether; monofluorobenzenes; nitrile; organic heterotetracyclic compound; pyrazoles | antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |